Stock listing

Immunitybio, Inc.

Selected listing: 26CA · MUN · EUR · DE

Immunitybio, Inc. (Munich:26CA), Health Technology. Latest release Aug 10, 2026: ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global…

26CA:MUNEURDEUpdated September 25, 2026

Ticker: Munich:26CA
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: Munich
Currency: EUR

Latest news from Immunitybio, Inc.

ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman

August 10, 2026

ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million

August 4, 2026

ImmunityBio Receives United Arab Emirates Marketing Authorization for ANKTIVA across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer

July 30, 2026

ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer

July 29, 2026

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

June 1, 2026

All Immunitybio, Inc. news →

Research Immunitybio, Inc.

Immunitybio, Inc. company profile

View the public company page for Immunitybio, Inc. on 6ix.

Immunitybio, Inc. news

Read company news and market updates connected to Immunitybio, Inc..

Immunitybio, Inc. investor events

Find investor webinars, events, and replay context for Immunitybio, Inc..